SHR A 1921
Alternative Names: SHR-1921; SHR-A 1921Latest Information Update: 03 Jan 2025
Price :
$50 *
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Developer Atridia; Suzhou Suncadia Biopharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Salivary gland cancer; Solid tumours
Most Recent Events
- 13 Sep 2024 Adverse events and efficacy data from a phase-I trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024),
- 07 Sep 2024 Efficacy and adverse events data from phase-I clinical trial in Solid tumours presented at 25th World Conference on Lung Cancer (WCLC-2024)
- 19 Jun 2024 Henan Cancer Hospital plans a phase II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) in June 2024 (NCT06465238)